What is the new drug for prostate cancer (and how to get it in Nigeria)?

Over the past decade, many new and promising treatment options for prostate cancer have emerged. Further new medicines are being developed at the moment, with new approvals in the field expected within the next couple of years.

This progress is encouraging. However, access to the latest prostate cancer therapies can vary significantly from one country to another.

If you're a patient in Nigeria seeking information on the new prostate cancer drugs available in your country, you’ve come to the right place. Below, we will explore the most recent approved treatments for prostate cancer. Including tips on how to access them in Nigeria, even if they are not yet available there.

What are the newest prostate cancer drugs in the world [2025]?

In the last few years, there have been 5 notable new drugs approved for prostate cancer, including one drug combination. Let's have a look at each of them.

#1: Xtandi (enzalutamide)

Xtandi has been approved for use in late-stage castration-resistant prostate cancer since 2012 ¹. Since then, it has gained additional approvals as well, as follows:

• for treating non-metastatic castration-resistant prostate cancer (CRPC);
• for treating metastatic castration-sensitive prostate cancer (mCSPC);
• for treating non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk of metastasis. Xtandi is the first androgen receptor signaling inhibitor approved in this earlier stage of prostate cancer. It can be combined with a gonadotropin-releasing hormone (GnRH) analog or used as a standalone treatment ².

Is Xtandi available in Nigeria?

Xtandi (enzalutamide) is not registered in the NAFDAC database. However, some online pharmacies in Nigeria seem to offer the medicine. While this may seem convenient, always verify if the pharmacy or wholesaler is legitimate. If you want to be sure that you are buying a genuine product, we recommend you access Xtandi in Nigeria from trusted wholesalers, like Everyone.org.

If you have a prescription for Xtandi, share it with our expert team and we'll support you in getting the medicine quickly and safely.

#2: Orgovyx (relugolix)

A newer medicine than Xtandi, Orgovyx was first approved in 2020 for use in advanced prostate cancer ⁴. Orgovyx is an oral medicine, easy to take at home, with or without food.

How successful is Orgovyx for prostate cancer?

According to the results of its clinical trial:

• 97% of patients taking Orgovyx lowered their testosterone within 29 days and kept it low until week 48 of treatment;
• After 15 days of treatment, 99% of men taking Orgovyx lowered their testosterone to levels under 50 ng/dL. Only 12% of the patients in the control group reported the same result.
• Prostate-specific antigen levels (PSA) after 3 months of treatment were 92% lower, on average, for patients taking Orgovyx vs the control group ⁴.

Is Orgovyx available in Nigeria?

Orgovyx isn't registered in the NAFDAC database. However, this doesn't mean that you cannot access it. If you have a prescription for this prostate cancer medicine from your doctor in Nigeria, you can order it right away via Everyone.org. We're experts in helping patients get medicines unavailable in their countries, and we'd be happy to assist you.

#3: Lynparza (olaparib)

Since 2020, Lynparza (olaparib) has been FDA-approved for the treatment of:

• HRR gene-mutated metastatic castration-resistant prostate cancer (including cancers with a BRCA mutation);
• BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). For this indication, Lynparza is approved in combination with abiraterone or prednisolone ⁵.

How successful is olaparib in prostate cancer?

Lynparza has been studied in multiple clinical trials. Some of the key reported results for prostate cancer are summarized below.

• Olaparib for metastatic castration-resistant prostate cancer with a BRCA mutation

  • The risk of cancer progression was 76% lower for patients taking Lynparza with abiraterone and prednisone ⁶.

• Olaparib for metastatic castration-resistant prostate cancer with an HRR mutation, as well as BRCA1, BRCA2, or ATM mutation

  • The risk of cancer progression was 66% lower for patients taking Olaparib vs the control group;
  • 33% of patients taking Lynparza saw their tumors shrink, compared to 2% in the control group ^6.

Is Lynparza available in Nigeria?

As of January 2025, not yet. However, if your treating doctor believes you could benefit from treatment with this new drug for prostate cancer, they can prescribe it to you. With a prescription, you can request Lynparza immediately, even if it's not approved or available in Nigeria. Simply click the button below.

#4: Akeega (niraparib/abiraterone acetate)

Akeega is the newest medicine for prostate cancer. It was FDA approved for BRCA-positive metastatic castration-resistant prostate cancer in August 2023 ⁷. It's currently the only FDA-approved medicine for its indication that combines two medicines into one tablet.

How successful is Akeega for prostate cancer?

According to the published results of its MAGNITUDE clinical trial, this is what we know about Akeega's success rate:

• The risk of cancer progression was 47% lower for patients taking Akeega, compared to the control group;
• The median overall survival for patients taking Akeega was 30.4 months, compared to 28.6 months in the control group ⁸.

Is Akeega (niraparib/abiraterone acetate) available in Nigeria?

No, Akeega is not on the NAFDAC register. However, patients can start the treatment as long as their treating doctor prescribes it. With a prescription, you can buy Akeega and receive it in Nigeria, even if it's not registered or available in the country. Get started by requesting the medicine via the button below.

#5: Xtandi (enzalutamide) + Talzenna (talazoparib)

As of 2023, Xtandi is also approved in combination with Talzenna (talazoparib) for use in patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) ⁹.

How successful is enzalutamide plus talazoparib for prostate cancer?

According to the recently reported results of the TALAPRO-2 study, the combination of these two medicines significantly improves survival in patients, compared to Xtandi (enzalutamide) alone ¹⁰. Additional key findings were:

• 67% of patients treated with Xtandi + Talzenna had their tumors shrink or disappear, compared to 40% in the control group;
• Patients with BRCA1/BRCA2 mutations had an 80% lower risk of cancer progression following treatment with Xtandi + Talzenna. For patients without the gene mutation, the risk was lowered by 32% ¹⁰.

Is Talzenna (talazoparib) available in Nigeria?

Yes, Talzenna is registered with NAFDAC and you will be able to get it locally if your doctor prescribes it. In case you are prescribed the combination of Talzenna and Xtandi, you can get Xtandi via Everyone.org, as it is currently not approved in Nigeria.

Always the newest drugs for prostate cancer

Unfortunately, registration processes for new medicines can take a long time in Nigeria. However, remember that you don't have to wait for treatment. You can always get the latest approved medicines from around the world as soon as you need them.

Simply contact our expert team at Everyone.org. We'll help you get the best treatment for prostate cancer in Nigeria. Of course, always following your doctor's recommendation.

References:

1. Xtandi FDA Approval History. Drugs.com, Accessed 15 January, 2025.
2. Pfizer and Astellas' Xtandi Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting. Drugs.com, Accessed 15 January 2025.
3. Clinical Trial Results | XTANDI® (enzalutamide). Xtandi, Accessed 15 January 2025.
4. Orgovyx FDA Approval History. Drugs.com, Accessed 15 January 2025.
5. Lynparza FDA Approval History. Drugs.com, Accessed 15 January, 2025.
6. Results of LYNPARZA. Lynparza, Accessed 15 January 2025.
7. Akeega FDA Approval History. Drugs.com, Accessed 15 January, 2025.
8. Efficacy. Akeegahcp.com, Accessed 15 January 2025.
9. Pfizer's TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval. Pfizer, 20 June 2023.
10. Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2). Clinicaltrials.gov, Accessed 15 January 2025.